Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Nagai

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
BMC Immunology|July 25, 2024
TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activationYosuke Ota, Ryosaku Inagaki, Yasuhiro Nagai, et al.
Domestic Animal Endocrinology|September 3, 2005
Cellular localization of IL-18 and IL-18 receptor in pig anterior pituitary glandYasuhiro Nagai, Kouichi Watanabe, Hisashi Aso, et al.
Cancer Research|February 12, 2013
scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumorsZheng Cai, Ting Fu, Yasuhiro Nagai, et al.
Toxicology Letters|September 1, 2010
Pro-IL-1β accumulation in macrophages by alendronate and its prevention by clodronateYosuke Shikama, Yasuhiro Nagai, Satoru Okada, et al.
Frontiers in Immunology|November 5, 2019
Foxp3 Post-translational Modifications and Treg Suppressive ActivityGuoping Deng, Xiaomin Song, Shigeyoshi Fujimoto, et al.
Experimental and Molecular Pathology|October 9, 2012
Molecular and biological role of the FOXP3 N-terminal domain in immune regulation by T regulatory/suppressor cellsGuoping Deng, Yan Xiao, Zhaocai Zhou, et al.
Archives of Oral Biology|December 19, 2012
In vitro cytotoxicity of zoledronate (nitrogen-containing bisphosphonate: NBP) and/or etidronate (non-NBP) in tumour cells and periodontal cellsYukinori Tanaka, Yasuhiro Nagai, Mina Dohdoh, et al.
Oncoimmunology|April 11, 2018
A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-γHongtao Zhang, Lian Lam, Yasuhiro Nagai, et al.
Innate Immunity|November 10, 2009
Muramyldipeptide augments the actions of lipopolysaccharide in mice by stimulating macrophages to produce pro-IL-1β and by down-regulation of the suppressor of cytokine signaling 1 (SOCS1)Yosuke Shikama, Toshinobu Kuroishi, Yasuhiro Nagai, et al.
Oncotarget|February 10, 2018
A spliced form of CD44 expresses the unique glycan that is recognized by the prostate cancer specific antibody F77Xi Chen, Yasuhiro Nagai, Zhiqiang Zhu, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
BMC Immunology|July 25, 2024
TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activationYosuke Ota, Ryosaku Inagaki, Yasuhiro Nagai, et al.
Domestic Animal Endocrinology|September 3, 2005
Cellular localization of IL-18 and IL-18 receptor in pig anterior pituitary glandYasuhiro Nagai, Kouichi Watanabe, Hisashi Aso, et al.
Cancer Research|February 12, 2013
scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumorsZheng Cai, Ting Fu, Yasuhiro Nagai, et al.
Toxicology Letters|September 1, 2010
Pro-IL-1β accumulation in macrophages by alendronate and its prevention by clodronateYosuke Shikama, Yasuhiro Nagai, Satoru Okada, et al.
Frontiers in Immunology|November 5, 2019
Foxp3 Post-translational Modifications and Treg Suppressive ActivityGuoping Deng, Xiaomin Song, Shigeyoshi Fujimoto, et al.
Experimental and Molecular Pathology|October 9, 2012
Molecular and biological role of the FOXP3 N-terminal domain in immune regulation by T regulatory/suppressor cellsGuoping Deng, Yan Xiao, Zhaocai Zhou, et al.
Archives of Oral Biology|December 19, 2012
In vitro cytotoxicity of zoledronate (nitrogen-containing bisphosphonate: NBP) and/or etidronate (non-NBP) in tumour cells and periodontal cellsYukinori Tanaka, Yasuhiro Nagai, Mina Dohdoh, et al.
Oncoimmunology|April 11, 2018
A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-γHongtao Zhang, Lian Lam, Yasuhiro Nagai, et al.
Innate Immunity|November 10, 2009
Muramyldipeptide augments the actions of lipopolysaccharide in mice by stimulating macrophages to produce pro-IL-1β and by down-regulation of the suppressor of cytokine signaling 1 (SOCS1)Yosuke Shikama, Toshinobu Kuroishi, Yasuhiro Nagai, et al.
Oncotarget|February 10, 2018
A spliced form of CD44 expresses the unique glycan that is recognized by the prostate cancer specific antibody F77Xi Chen, Yasuhiro Nagai, Zhiqiang Zhu, et al.
Pageof 4